Current Report Filing (8-k)
September 15 2021 - 9:17AM
Edgar (US Regulatory)
0001522602
false
0001522602
2021-09-14
2021-09-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
To Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of Report: September 14, 2021
(Date
of earliest event reported)
COHBAR,
INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-38326
|
|
26-1299952
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer
Identification
No.)
|
1455
Adams Drive, Suite 2050
Menlo
Park, CA 94025
(Address
of principal executive offices and zip code)
(650)
446-7888
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting
material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange
on which registered
|
Common
Stock
|
|
CWBR
|
|
Nasdaq
Capital Market
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
COHBAR,
INC.
FORM
8-K
Item 5.02
|
Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
On September 14, 2021, the board of directors
(the “Board”) of CohBar, Inc. (the “Company”) appointed Joanne Yun to serve as director of the Company, effective
immediately.
Dr.
Yun has over 30 years of experience in board and executive level positions in the medical industry with global pharmaceutical and biotechnology
companies. She is a partner at Egon Zehnder International, a leadership advisory firm and is currently a member of the firm’s Health
Practice, where she leads their Research & Development segment. Prior to joining Egon Zehnder in June 2007, Dr. Yun served as a director
in the Global Oncology Business Unit for Bayer HealthCare Pharmaceuticals from April 2001 to April 2007, with responsibility for oncology
program management and new product planning. Dr. Yun started her career in February 1998 with Bayer AG and continued there until March
2001 in various research management roles. Dr. Yun earned a bachelor’s degree in chemistry and French from Amherst College and
a Ph.D. in chemistry from the Massachusetts Institute of Technology. She was a National Institutes of Health Postdoctoral Fellow at The
Scripps Research Institute and is a member of the American Society of Clinical Oncology, the American Society of Hematology, and the
American Chemical Society.
In connection with her appointment as a member
of the Board, Dr. Yun was granted stock options to purchase 200,000 shares of the Company’s common stock, at an exercise price of
$1.18 per share (the “Option”). The Option will vest and become exercisable in equal monthly installments over a period of
four years based on Dr. Yun’s continued service to the Company during the vesting period. Dr. Yun will also receive annual cash
compensation of $60,000 in consideration of her service as a director.
Signature
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
COHBAR, INC.
|
|
|
(Registrant)
|
|
|
|
|
September 15, 2021
|
|
By:
|
/s/ Jeffrey F. Biunno
|
(Date)
|
|
|
Jeffrey F. Biunno
|
|
|
|
Chief Financial Officer
|
2
CohBar (NASDAQ:CWBR)
Historical Stock Chart
From Jun 2024 to Jul 2024
CohBar (NASDAQ:CWBR)
Historical Stock Chart
From Jul 2023 to Jul 2024